In short
This article explores the ongoing clinical trial of BAY 3018250, a promising new drug being studied for the treatment of proximal deep vein thrombosis (DVT). The trial aims to assess the effectiveness and safety of BAY 3018250 in patients with this condition, comparing it to standard treatments. We'll discuss the study's objectives, eligibility criteria, and potential implications for future DVT treatment.
At a glance
- Drug Name
- BAY 3018250
- Condition Studied
- Proximal Deep Vein Thrombosis (DVT)
- Study Type
- Randomized, double-blind, placebo-controlled, multi-center study
- Primary Objectives
- 1. Quantify effect on clot lysis; 2. Assess safety
- Key Eligibility Criteria
- 1. Age 18 or older; 2. Acute symptomatic proximal DVT; 3. Symptoms for 14 days or less; 4. Weight between 50 to 130 kg
- Main Outcome Measures
- 1. Change in clot burden over time; 2. Occurrence of bleeding events
- Study Duration
- 90 days per participant
What is BAY 3018250?
BAY 3018250 is a new medication being developed by Bayer AG. It is currently undergoing clinical trials to evaluate its effectiveness and safety in treating certain blood clot conditions. The drug is administered as a concentrate for solution for infusion, which means it's given directly into the bloodstream through a vein.
What Medical Condition Does BAY 3018250 Treat?
BAY 3018250 is being studied for the treatment of proximal deep vein thrombosis (DVT). DVT is a serious condition where blood clots form in the deep veins, usually in the legs. "Proximal" refers to clots that occur in the upper part of the leg or thigh. These clots can be dangerous because they can break loose and travel to the lungs, causing a potentially life-threatening condition called pulmonary embolism.
How Does BAY 3018250 Work?
While the exact mechanism of action is not fully described in the provided information, BAY 3018250 appears to be designed to help with clot lysis. This means it may help to break down or dissolve blood clots. The study aims to quantify the effect of BAY 3018250 on clot lysis in patients with proximal DVT.
Current Clinical Trial Information
A clinical trial is currently underway to study BAY 3018250. This trial is described as a randomized, double-blind, placebo-controlled, multi-center study. Let's break down what this means:
- Randomized: Participants are randomly assigned to different treatment groups.
- Double-blind: Neither the participants nor the researchers know who is receiving the actual drug and who is receiving a placebo.
- Placebo-controlled: Some participants will receive a placebo (a substance with no active ingredients) instead of the actual drug.
- Multi-center: The study is being conducted at multiple hospitals or research centers.
This type of study design helps ensure that the results are as unbiased and reliable as possible.
Who Can Participate in the Study?
The study has specific criteria for who can participate. Here are some key points:
- Participants must be 18 years or older
- Both males and females can participate (females must be postmenopausal or have had a hysterectomy)
- Participants must have acute symptomatic proximal deep vein thrombosis (DVT) confirmed by ultrasound
- Symptoms must have been present for 14 days or less
- The DVT must involve at least one of the following veins: popliteal, femoral, common femoral, or external iliac vein
- Participants must weigh between 50 to 130 kg
There are also several conditions that would prevent someone from participating, such as:
- Having a pulmonary embolism (blood clot in the lung) that requires specific treatments
- Active bleeding or high risk of bleeding
- Recent stroke, heart attack, brain bleeding, or major surgery
- Active cancer
- Use of certain medications
These criteria help ensure the safety of participants and the reliability of the study results.
How is the Study Designed?
The study is designed to test different doses of BAY 3018250 against a placebo. Participants will be divided into three groups:
- BAY 3018250 Dose 1 group
- BAY 3018250 Dose 2 group
- Placebo group
Each participant will receive a single dose of their assigned treatment. The study will last for 90 days, including one overnight stay in the hospital after receiving the treatment. Throughout the study, participants will undergo various tests and assessments to monitor the effects of the treatment.
How Will the Effectiveness of BAY 3018250 be Measured?
The study will use several methods to measure how well BAY 3018250 works:
- Clot burden assessment: Researchers will use ultrasound to measure the size of the blood clot over time (at 6 hours, 24 hours, 7 days, 30 days, and 90 days after treatment).
- Pain assessment: Participants will rate their leg pain severity at various time points.
- Functional status: The study will assess how well participants can function after the treatment.
- Recurrence of blood clots: The number of participants who experience new blood clots will be tracked.
These measurements will help determine if BAY 3018250 is effective at dissolving blood clots and improving symptoms associated with DVT.
Safety Considerations
An important part of this study is to assess the safety of BAY 3018250. The researchers will be closely monitoring for any side effects, particularly bleeding events. They will track the number of participants who experience major or clinically relevant non-major bleeding up to 15 days after receiving the treatment.
It's important to note that while this drug shows promise, it is still in the testing phase. More research is needed to fully understand its effectiveness and safety profile. Patients should always consult with their healthcare providers about the most appropriate treatments for their specific condition.